If you have heard that estrogen patches are "safer than pills," the better version is more precise: route can matter for venous clot risk, but it does not make hormone therapy automatically safe.
A 2015 systematic review and meta-analysis compared oral and transdermal estrogen therapy across observational studies. Compared with transdermal estrogen, oral estrogen was associated with higher risk of a first venous thromboembolism, with risk ratio 1.63. Deep vein thrombosis risk was also higher, with risk ratio 2.09. [1]
That is a route signal. It is not a free pass.
Why oral and transdermal estrogen can behave differently
Oral estrogen passes through the liver first. That first-pass effect can change clotting-related proteins and inflammatory markers in ways that may raise venous clot risk in some patients. Transdermal estrogen enters through the skin and avoids much of that first-pass liver exposure.
American College of Obstetricians and Gynecologists summarized the clinical implication in its committee opinion on route and venous thromboembolism. It stated that oral estrogen may exert a prothrombotic effect, while transdermal estrogen appears to have little or no effect on some prothrombotic substances. American College of Obstetricians and Gynecologists also said clinicians should consider the possible thrombosis-sparing properties of transdermal forms when prescribing. [2]
That is why route belongs in the intake. It is not a cosmetic preference.
What the meta-analyses found
The 2015 review found oral estrogen was associated with higher first venous thromboembolism risk than transdermal estrogen. It also found higher deep vein thrombosis risk and a possible stroke signal, while myocardial infarction was not clearly increased. [1]
An earlier review and updated meta-analysis found a pooled venous thrombosis risk ratio of 1.9 for oral estrogen and 1.0 for transdermal estrogen among postmenopausal women. [3]
Those results are mostly observational, so they can be affected by who was prescribed which route. Still, the pattern is consistent enough that route-specific counseling is standard in careful hormone-therapy discussions.
| Evidence signal | What it found | What it does not establish |
|---|---|---|
| 2015 meta-analysis | Oral estrogen had higher first venous thromboembolism risk than transdermal estrogen, relative risk 1.63; deep vein thrombosis relative risk 2.09. [1] | It was based on observational studies, so prescribing differences and baseline risk may influence the estimate. |
| Updated oral-vs-transdermal review | Pooled venous thromboembolism risk ratio was 1.9 for oral estrogen users and 1.0 for transdermal estrogen users. [3] | It does not make transdermal estrogen appropriate for every woman with clot risk. |
| ESTHER case-control study | Adjusted venous thromboembolism odds ratio was 4.2 for oral estrogen and 0.9 for transdermal estrogen compared with nonuse. [5] | It is not a randomized trial and should not be used as a stand-alone eligibility rule. |
| 2025 higher-risk review | In included higher-risk populations, transdermal estrogen conferred no increased venous thromboembolism risk, while oral estrogen plus progestogen had the highest increased risk. [4] | The authors still called for more contemporary data. |
This is the evidence limit that matters for a reader: the route signal is clinically useful, but the evidence is not a guarantee. It should establish the clinician conversation, not replace it.
Higher-risk women need the route question most
A 2025 systematic review focused on menopausal hormone therapy in postmenopausal women at higher risk of venous thromboembolism. It concluded that, in women with venous thromboembolism risk factors, transdermal estrogen conferred no increased risk in the included evidence, while oral estrogen with progestogen carried the highest increased risk. The authors also noted the need for more contemporary data. [4]
For a patient, the plain-language point is this: if clot risk is part of the story, the route conversation becomes more important, not less.
Risk factors that should slow the visit down include prior venous thromboembolism, known thrombophilia, obesity, smoking, immobilization, fracture, major surgery, older age, active cancer history, stroke history, coronary disease, migraine complexity, and medications that change clot risk.
Route does not replace eligibility screening
A patch does not solve every hormone-therapy problem. Systemic estrogen still requires a clinician to review:
- Last period and age.
- Time since menopause.
- Uterus status and need for endometrial protection.
- Breast cancer, endometrial cancer, stroke, clot, heart attack, and liver history.
- Blood pressure, lipids, diabetes risk, smoking, migraine, and medication interactions.
- Dose, formulation, progestogen choice, and treatment goal.
If the treatment goal is vague, such as general anti-aging, the risk-benefit review becomes weaker. If the treatment goal is severe hot flashes or night sweats, the discussion is clearer.
The 2022 Menopause Society hormone-therapy statement makes this broader than clot risk. It says hormone-therapy risks differ by type, dose, duration, route, timing of initiation, and whether a progestogen is used. It also describes a more favorable benefit-risk ratio for many symptomatic women younger than 60 or within 10 years of menopause onset who have no contraindications, and a less favorable ratio when therapy is initiated after age 60 or more than 10 years from menopause onset. [6]
Current estrogen-progestin labeling also keeps the contraindication screen explicit. A DailyMed estradiol/norethindrone acetate label lists contraindications including undiagnosed abnormal genital bleeding, breast cancer or history of breast cancer, estrogen-dependent neoplasia, active deep vein thrombosis or pulmonary embolism or history of those conditions, active arterial thromboembolic disease such as stroke or heart attack or history of those conditions, hepatic impairment or disease, and known thrombophilic disorders. [7]
That means the route decision comes after the safety screen, not before it.
Where this fits in HRT care
The broader hormone therapy overview covers timing, uterus status, Women's Health Initiative context, and symptom targets. Route is the narrower prescribing decision here.
| Decision point | Why it matters |
|---|---|
| Oral estrogen | More concern for liver first-pass clotting effects and venous thromboembolism signal. [1] [2] |
| Transdermal estrogen | Often considered when clot-risk markers, triglycerides, or route-specific risk are part of the discussion. [2] |
| Uterus present | Systemic estrogen requires endometrial protection. |
| Prior venous thromboembolism or stroke | May make systemic therapy inappropriate or specialist-led, regardless of route. |
| More than 10 years since menopause | Overall benefit-risk ratio may be less favorable, so route is only one part of screening. |
This is the clinically useful message: the content can help a reader ask a better eligibility question, not self-prescribe a route.
Who fits a route conversation, and who should slow down?
| Scenario | Route conversation | Safer next step |
|---|---|---|
| Bothersome hot flashes, under 60 or within 10 years of menopause, no contraindications | Oral versus transdermal route can be discussed alongside dose, symptom target, and uterus status. [6] | Compare route, dose, progestogen need, follow-up, and red flags. |
| Obesity, smoking, recent fracture, immobilization, strong family history, or migraine complexity | Transdermal estrogen may be worth discussing because baseline venous thromboembolism risk is part of the decision. [2] [4] | Review personal clot/stroke risk before choosing any systemic route. |
| Prior deep vein thrombosis, pulmonary embolism, stroke, heart attack, known thrombophilia, active liver disease, breast cancer history, or unexplained bleeding | Route alone is not enough to make systemic therapy routine. [7] | Specialist-led review or nonhormonal/local options may be safer. |
| Vaginal dryness, painful sex, recurrent urinary symptoms without hot flashes | A systemic patch may be more exposure than the symptom requires. | Ask whether local genitourinary syndrome of menopause therapy fits before systemic hormone replacement therapy. |
| Anti-aging, weight loss, skin, hair, or vague optimization as the goal | Route does not fix a weak indication. | Define the diagnosis and endpoint first. |
The route question is strongest when the symptom target is real and the main uncertainty is vascular risk. It is weakest when "patch" is being used as a marketing shorthand for safe hormones.
Red flags before or during estrogen therapy
Do not troubleshoot possible clot or stroke symptoms by changing the dose at home. Chest pain, sudden shortness of breath, coughing blood, one-sided leg swelling or pain, sudden weakness or numbness, facial droop, trouble speaking, sudden vision change, or severe new headache need urgent evaluation.
Postmenopausal bleeding also changes the path. Bleeding after menopause, including bleeding that happens while using hormone therapy, needs clinician evaluation rather than an assumption that the patch dose is wrong. For that narrower issue, see bleeding on hormone replacement therapy after menopause.
What to ask a clinician
Ask:
- Does my clot, stroke, heart, migraine, smoking, cancer, surgery, or immobilization history change systemic estrogen eligibility?
- If systemic estrogen fits, does transdermal or oral route better match my risk profile?
- If I have a uterus, what progestogen plan protects the endometrium?
- What symptoms or side effects should make me stop and call?
- How often should route, dose, blood pressure, bleeding, and symptom response be reviewed?
Bottom line
Transdermal estrogen may have a lower venous clot-risk profile than oral estrogen in observational evidence, and major guidance treats route as a real prescribing variable. But route is not a shortcut around contraindications. The right next step is a clinician-led hormone-therapy review that matches symptom target, timing, uterus status, clot risk, and formulation.
Related reading:
- Vaginal Estrogen After Menopause Is Not the.
- What Is Perimenopause? A Pattern, Not a One-Day Switch.
- Who Should Avoid hormone replacement therapy After Menopause? Contraindications.
- Starting hormone replacement therapy After 60.
References
[1] Mohammed K, Abu Dabrh AM, Benkhadra K, et al. Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2015;100(11):4012-20. doi:10.1210/jc.2015-2237 https://pubmed.ncbi.nlm.nih.gov/26544651/
[2] ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol. 2013;121(4):887-890. doi:10.1097/01.aog.0000428645.90795.d9 https://pubmed.ncbi.nlm.nih.gov/23635705/
[3] Olié V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol. 2010;17(5):457-63. doi:10.1097/moh.0b013e32833c07bc https://pubmed.ncbi.nlm.nih.gov/20601871/
[4] Hicks A, Robson D, Tellis B, Smith S, Dunkley S, Baber R. Safety of menopause hormone therapy in postmenopausal women at higher risk of venous thromboembolism: a systematic review. Climacteric. 2025;28(5):497-509. doi:10.1080/13697137.2025.2503874 https://pubmed.ncbi.nlm.nih.gov/40488293/
[5] Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-5. doi:10.1161/circulationaha.106.642280 https://pubmed.ncbi.nlm.nih.gov/17309934/
[6] “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/gme.0000000000002028 https://pubmed.ncbi.nlm.nih.gov/35797481/
[7] DailyMed. Estradiol and norethindrone acetate tablet prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c786d6-91bd-4eea-9455-ff2abc08372f